# **Morning Insight**



Cash BSE

Cach NSE



	% Chg			
	4-Jul	1 Day	1 M th	3 Mths
Indian Indices				
SENSEX Index	39,908	0.2	(0.4)	2.7
NIFTY Index	11,947	0.3	(0.6)	2.4
NSEBANK Index	31,472	0.3	(0.4)	4.6
NIFTY 500 Index	9,777	0.2	(1.0)	0.9
CNXMcap Index	17,814	(0.0)	(1.7)	(2.4)
BSESMCAP Index	14,337	0.1	(3.8)	(4.7)
World Indices				
Dow Jones	26,966	0.7	6.4	2.2
Nasdaq	8,170	8.0	8.5	3.5
FTSE	7,604	(0.1)	5.3	2.1
NIKKEI	21,702	0.3	4.4	(0.5)
Hangseng	28,796	(0.2)	7.3	(3.6)
Shanghai	3,005	(0.3)	5.0	(7.4)
Value traded (Rs cr)		4-Jul	%	Chg Day

Casilival	20,001		0.5
Derivatives	1,971,511		101.2
Net inflows (Rs cr)	3-Jul	MTD	YTD
FII	(1,281)	(3,697)	75,383
Mutual Fund	327	(220)	8,514
Nifty Gainers & Losers	Price (Rs)	Chg (%)	Vol (mn)
Gainers	()	(70)	()
UPL Ltd	698	7.1	12.5
Bharti Airtel	363	2.7	8.4

2.003

704

96

495

1,290

19

(3.5)

(2.9)

(2.9)

20 001

19.1

30.9

108.1

73

2.9

69.2

6 5

# Advances / Declines (BSE)

Indiabulls Housing

Yes Bank Ltd

Tata Steel

Titan Co Ltd


Losers

4-Jul	Α	В	Т	Total	% total
Advances	257	465	44	766	100
Declines	197	501	36	734	96
Unchanged	4	36	13	53	7

Commodity			% Chg	
•	4-Jul	1 Day	1 M th	3 Mths
Crude (US\$/BBL)	63.3	(0.1)	4.3	(10.1)
Gold (US\$/OZ)	1,416.1	(0.2)	6.6	9.7
Silver (US\$/0Z)	15.3	(0.1)	3.2	1.1
Debt / Forex Market	4-Jul	1 Day	1 M th	3 Mths
10 yr G-Sec yield %	6.7	6.8	7.0	7.3

# Nifty

Re/US\$



Source: Bloomberg

# **News Highlights**

- India expects economic growth to rebound from a five-year low without sacrificing budget goals, as it pins hopes on political stability to revive demand and investments. Real gross domestic product growth for the fiscal year started April 1 is projected at 7 percent. (Mint)
- Weeks after India raised duties on 28 American goods, the US on Thursday dragged New Delhi to the World Trade Organization (WTO) for according "less favorable treatment" to its products. (Mint)
- The Ministry of Corporate Affairs has ordered a probe in **Jet Airways** and its group companies by the Serious Fraud Investigation Office (SFIO). The order is supposedly on the basis of an inspection report by MCA Western Director. (ET)
- Dewan Housing Finance Corp has delayed payment on some of its obligations, plans to ask banks to lend 15 billion rupees (\$217 million) every month to help revive the company. (ET)
- ▶ The Competition Commission has ordered a detailed probe against carmaker Maruti Suzuki for alleged resale price maintenance arrangement with dealers. (ET)
- Yes Bank has acquired over 9% shares of battery maker Eveready by invoking pledged shares following loan default by a group company. (BS)
- Tata Motors has decided to implement periodic production cuts at its passenger-car plants and focus on retail sales to prop up dealerships amid an industry-wide slowdown in passenger vehicle sales. (ET)
- In a bid to become a universal bank, Srei has decided to consolidate all its lending business into one vertical - Srei Equipment Finance. (BS)
- GMR Infrastructure Ltd has signed an agreement with Adani Power Ltd for sale of entire stake of 47.62% in GMR Chhattisgarh Energy Ltd (GCEL) to Adani Power for an estimated value of Rs 30 bn. (ET)
- The National Company Law Appellate Tribunal has directed the National Company Law Tribunal to pass orders on consolidating the bankruptcy proceedings of Videocon group companies within three weeks. (ET)
- ▶ L&T Finance Holdings arm received \$550 million in an External Commercial Borrowing investment round from World Bank's arm, BNP Paribas, Citi Bank and DBS Bank. (ET)
- ▶ **Usha Martin** has completed the transfer of the operative iron-ore mine and coal mine under development to Tata Sponge Iron. (BS)
- Hindalco will have to tackle European antitrust objections on its plan to buy aluminum producer Aleris Corporation to expand as a supplier to the car industry. (Mint)

# What's Inside

Company Visit Note: Galaxy Surfactants Ltd (GSL)

Source: ET = Economic Times, BS = Business Standard, FE = Financial Express, IE = Indian Express, BL = Business Line, BQ = BloombergQuint, Tol: Times of India, BSE = Bombay Stock Exchange, MC = Moneycontrol

**Financial Summary** 



# **Company Visit Note**

#### **Stock Details PRICE Rs. 1262 NOT RATED**

GALAXY SURFACTANTS LTD (GSL)

Market cap (Rs mn) 44882 1410 / 872 52-wk Hi/Lo (Rs) 10 92 35

Face Value (Rs)	:	1
3M Avg. daily vol (Nos)	:	18,09
Shares o/s (mn)	:	3
Source: Bloomberg		

Y/E Mar (Rs mn) FY17 FY18 FY19 Revenue 22.480 24.625 27.630 Growth (%) 20.1 9.5 12.2 **EBITDA** 2.714 2.877 3,534 EBITDA margin (%) 12.1 11.7 12.8 PAT 1,476 1,580 1,910 **EPS** 41.6 44.6 53.9 EPS Growth (%) 2.5 21.7 42.9 247 BV (Rs/share) 203 162 Dividend/share (Rs) 7.0 8.0 6.0 **ROE (%)** 21.8 25.7 22.0 ROCE (%) 27.9 25.8 24.5 P/E (x) 30.3 28.3 23.4 EV/EBITDA (x) 17.6 16.5 13.3 P/BV(x) 7.8 5.1

Source: Company, Kotak Securities - PCG

#### **Shareholding Pattern (%)**

Mar 19	Dec-18	Sep-18
70.9	70.9	70.9
3.1	3.1	3.1
8.7	8.7	8.7
17.3	17.3	17.3
	70.9 3.1 8.7	3.1 3.1 8.7 8.7

#### Price Performance (%)

(%)	1M	3M	6M
Galaxy Surfactants	7.9	23.0	3.8
Nifty	(0.6)	3.0	11.4

Source: Bloomberg

Source: Bloomberg

#### Price chart (Rs)



Jatin Damania jatin.damania@kotak.com +91 22 6218 6440

Galaxy Surfactants (GSL) is currently India's largest manufacturer of vegetable oil (oleochemical)-based surfactants and specialty care products for the home and personal care (HPC) industries, with an installed capacity of ~368,000 tonnes. The company recently expanded its performance surfactants (PS) capacity by ~50,000 tonnes, which will suffice its volume growth for the next two to three years. GSL is a good proxy to Indian FMCG premiumisation, and has a strong franchise with dominant market share in India and Africa-Middle East markets.

# **Key highlights**

- GSL primarily operates in (i) performance surfactants (PS) and (ii) specialty ingredients (SI). PS and SI accounts for 63% and 37% of revenue, respectively. With over 200+ products (60 are patented), it serves 1750+ clients in 75+ countries with export accounting for 63% of total sales. The company is the preferred supplier to global, regional and local FMCG brands with a sales share of 56%, 10% and 34%, respectively.
- ☐ The company recently expanded its PS capacity by 50,000 at Jhagadia. Ramp-up of the new capacity and better utilization at existing facilities (currently at ~72%) will help achieve expected volume growth of ~8-10% per annum. In addition, GSL has outlined capex of Rs1.5 bn for FY20 for broadening the specialty care product portfolio and R&D. The company added few products in the recent past. They are GLI-21, Non-Toxic Preservatives such as Galguard Trident and NT.
- ☐ The global surfactants industry (size US\$ 35bn) is growing at 4-5% annually and expected to touch US\$ 45bn by FY24, driven by 1) volume growth in developing nations due to lower penetration of HPC (Home & Personal Care) products and 2) value growth from developed nations. India surfactants industry is expected to grow from US\$1.5 bn to US\$2.3 bn in 2024.
- The AMET (Africa, Middle East and Turkey) region accounts for a significant (~32%) portion of GSL's revenue. During FY19, AMET region degrew by 4.7% YoY however, excluding Egypt the rest of Africa, ME, and Turkey reported healthy volume growth at 17.1%. Egypt contributes ~45% to AMET market sales and ~19% to overall revenue in FY18.
- Both the segments (PS and SI) are expected to grow in the coming years on the back of capacity expansion. In addition, increasing share of SS and focus on R&D, will help the company to strengthen its operating performance and profitability in the coming years. Top 10 customers' accounts for ~55% of the revenue (concentration risk).

#### Valuation and Outlook

GSL is taking advantage of the opportunities available both in the global as well as domestic markets by adding of new capacities, customer acquisition, investment in R&D to develop newer specialty care products and cross sell products to existing customers. It leverages its long-standing relationships with clients to supply specialty personal care ingredients, which generate better margins. Despite having a higher contribution from PS, GSL has been able to deliver return ratios of over 20% in the last four years. The company focus on enhancing its product mix gradually over the next 4-5 years. This will help the



company to improve its EBITDA/tonne from the current levels of Rs16,400 and return ratios. However, in FY20E, due to increased share of PS (benefit of capacity expansion) EBITDA/tonne is likely to remain in the range of Rs15,000-17,000. At CMP, the stock is trading at 23.4x FY19 earnings.

# Favourable macros with share of oleochemicals in the HPC segments on the rise

Surfactants can be prepared from either petrochemicals or oleochemicals. Over the past few years, the use of oleochemicals in the surfactants sector has continued to rise as awareness on natural products increases. GSL is primarily engaged in the manufacture of natchem (oleo) based surfactants (c.70% of the GSL's portfolio is natchem-based) and is hence clearly in a position to benefit from this shift. According to the Acmite, the surfactants market, valued at ~US\$ 35bn at the end of 2018 is projected to grow at a CAGR of 4.4% to touch ~US\$ 45bn in 2024. The larger portion of the growth is expected to come from Asia Pacific region which is expected to grow at a CAGR of 5.8% during the same period. Amongst the category, HPC could be the fastest growing segment, which is expected to grow from ~US\$ 7bn to ~US\$ 10bn during the same period.

#### Surfactant market (US\$ bn)

#### Region 2015 2018 2024 8.52 10.52 Western Europe 7.66 North America 8.74 9.77 12.2 Asia Pacific 13.22 7.97 9.44 Japan 2.61 2.88 3.52 Rest of the World 4.26 5.7 3.68 30.65 34.88 45.16 Total

Source: Company

#### End Use Surfactant market (US\$ bn)

Category	2015	2018	2024
Personal Care6.13	7.29	10.27	
Household Cleaning	10.73	11.87	14.49
Industrial Application	9.81	11.23	14.7
I & I Cleaning	1.99	2.22	2.74
Others	1.99	2.28	2.96
Total	30.65	34.88	45.16

Source: Company

As far as the domestic market is concerned, the India surfactants industry is expected to grow from US\$1.5 bn to US\$2.3 bn in 2024 and in term of volume it is expected to post a CAGR of ~6% for the next 4-5 years. As far as GSL is concerned, AMET region, which accounts for a significant portion of revenue, is expected to grow from US\$ 0.9bn to US\$ 1.2 bn in 2024.

India - End Use Surfactant market (US\$ bn)

Category	2015	2018	2024
Household Cleaning	0.42	0.49	0.65
I & I Cleaning	0.11	0.13	0.17
Personal Care	0.24	0.3	0.47
Industrial Application	0.45	0.54	0.78
Others	0.13	0.15	0.21
Total	1.35	1.61	2.28

Source: Company

# Large capex out of the way; internal accrual to fund future capex

During FY12-14, Galaxy undertook a major capex plan of ~Rs3 bn and set up a Greenfield expansion at Jhagadia as well as a new production facility in Egypt. With an installed capacity of ~3.68 lakh tonnes (current utilisation ~72%), its seven state of art facilities, zero discharge manufacturing plants are located in India (5), Egypt (1) and the US (1). Egypt facility is operating at lower capacity due to headwinds in terms of down-trading in Egypt on account of high inflation and slowdown in end-markets in 20FY19 and 30FY19.



#### **Manufacturing facilities**

Location	No.of units	Capacity (tonnes)
Tarapur, Maharashtra	3	31,995
Taloja, Maharashtra	1	160,500
Jhagadia, Gujarat	1	83,500
Suez, Egypt	1	91,500
New Hampshire, USA	1	600

Source: Company


The company recently expanded its PS capacity by 50,000 at Jhagadia, which has increased its overall capacity by ~12%. Ramp-up of the new capacity and better utilization of existing facilities (currently at ~72%) will help achieve expected volume growth of ~8-10% per annum. In addition, GSL has outlined capex of Rs1.5 bn for FY20 for broadening the specialty care product portfolio and R&D. Capex details are outlined below:

- Rs800 mn for pilot plant for new product R&D,
- Rs400 500 mn for TRI-K,
- · Rs80 mn for R&D infrastructure, and
- · Remaining is allocated for debottlenecking activities.

# Strong R&D capabilities

In line with its motto 'Consumer to chemistry', Galaxy undertakes collaborative product development with its customers, which helps its customers choose the right technology with the right applications. This model has not only allowed the company to adopt an innovation funnel model, which allows it to customise products in line with customer expectations and end-user preferences, but also simultaneously permits shorter lead times. Since 2002, Galaxy has been granted a total of 60 patents globally.

# **Product Evolution over the years**



Source: Company

# Focus on value added specialty surfactants


It recently added new specialised surfactants – amino acid based for foaming and mildness, few products for sparkling effect and appearance, it also launched Glutamate, Glycinate, Torrets, Sarcosinate, GLI 21 and other sulfate free products. The higher share of SI in the recent past has helped the company to improve its EBITDA/t to Rs16,458. The management had indicated that, ratio of PS and SI will continue to remain in the level of 60:40, with a variation for a year or so, depending upon the commissioning of capacity.

Source: Company




Management stated that in FY20, the share of PS is likely to increase (benefit of capacity expansion flows in), which will help the company to maintain its EBITDA/tonne in the range of Rs15,000-17,000. In FY21, the contribution from SS will again bounce back to the level of 35-40%, backed by new capacity.

#### Volume grew at 7% CAGR



# EBITDA/T trend (Rs)




Source: Company

# Expanding into newer markets in AMET to offset headwinds in Egypt

The AMET region accounts for a significant portion of GSLS' revenue ~30% in FY19. The company faced headwinds due to down-trading in Egypt on account of high inflation and slowdown in end-markets starting H2FY19. The AMET market shrank by 5% YoY in volume terms during (excluding Egypt, it grew at 9%). Egypt contributes ~45% to AMET market sales and ~19% to overall revenue in FY18. To mitigate this, the company is actively exploring adjacent geographies such as Kenya, Libya, Lebanon, UAE, and Jordan. It will help in improving volumes gradually; however, it is likely to increase logistic costs for supplying materials to newer markets. Management expects a recovery in the next few quarters as the company has diverted the capacity to other growing countries and received approvals.


# Geography wise volume breakup (tonnes



Source: Company




# 7% volume CAGR (tonnes)...




Source: Company

# ....supported ~7% revenue CAGR (Rs Bn)




Source: Company

# EBITDA/T (Rs) improved over the years




Source: Company

# ...coupled with firm realisation (Rs/t)...




Source: Company

#### EBITDA margin in the range of 11.5-13%



Source: Company

# **Return ratios over 20%**



Source: Company



# **Financials: Consolidated**

# **Profit and Loss Statement (Rs mn)**

(Year-end Mar)	FY16	FY17	FY18	FY19
Net sales	18,710	22,480	24,625	27,630
growth (%)	(4.3)	20.1	9.5	12.2
Operating expenses	16,390	19,767	21,748	24,096
EBITDA	2,320	2,714	2,877	3,534
growth (%)	23.1	17.0	6.0	22.8
Depreciation & amortisation	452	472	485	512
EBIT	1,868	2,242	2,392	3,022
Other income	59	104	101	47
Interest paid	312	272	306	300
PBT	1,615	2,074	2,188	2,769
Tax	603	598	607	859
Effective tax rate (%)	37.4	28.8	27.8	31.0
Net profit	1,011	1,476	1,580	1,910
Reported Net profit	1,011	1,476	1,580	1,910
Non-recurring items	-	-	-	-
Adjusted Net profit	1,011	1,476	1,580	1,910
growth (%)	43.8	2.5	21.7	42.9

Source: Company, Kotak Securities - Private Client Research

# **Cash flow Statement (Rs mn)**

(Year-end Mar)	FY16	FY17	FY18	FY19
Pre-tax profit	1,635	1,476	1,580	2,769
Depreciation	452	472	485	512
Chg in working capital	54	(1,135)	(897)	82
Total tax paid	(618)	(568)	(583)	(859)
Other operating activities	318	866	855	253
Operating CF	1,842	1,110	1,442	2,757
Capital expenditure	(666)	(426)	(552)	(1,232)
Chg in investments	-	-	-	(1)
Other investing activities	16	(4)	20	47
Investing CF	(650)	(430)	(532)	(1,186)
FCF	1,176	685	890	1,525
Equity raised/(repaid)	-	-	-	-
Debt raised/(repaid)	(364)	(133)	(485)	(557)
Dividend (incl. tax)	-	(173)	(127)	(330)
Other financing activities	(820)	(257)	(285)	(300)
Financing CF	(1,184)	(563)	(897)	(1,188)
Net chg in cash & bank bal.	8	117	14	384
Closing cash & bank bal	147	257	271	250

Source: Company, Kotak Securities - Private Client Research

# Balance sheet (Rs mn)

(Year-end Mar)	FY16	FY17	FY18	FY19
Cash & Bank balances	147	257	271	250
Other Current assets	5,692	7,307	8,918	8,724
Investments	0	1	1	-
Net fixed assets	4,757	4,575	4,648	5,938
Goodwill & intangible assets	108	87	69	75
Other non-current assets	300	646	648	692
Total assets	11,004	12,872	14,554	15,680
Current liabilities	3,009	3,531	4,158	4,050
Borrowings	3,391	3,340	2,931	2,542
Other non-current liabilities	187	253	277	320
Total liabilities	6,587	7,123	7,366	6,913
Share capital	355	355	355	355
Reserves & surplus	4,063	5,395	6,833	8,413
Shareholders' funds	4,417	5,749	7,188	8,767
Minority interest	-	-	0	0
Total equity & liabilities	11,004	12,872	14,554	15,680

Source: Company, Kotak Securities - Private Client Research

# **Ratio Analysis**

(Year-end Mar)	FY16	FY17	FY18	FY19		
Profitability and return ratios (%)						
EBITDAM	12.4	12.1	11.7	12.8		
EBITM	10.3	10.4	10.1	11.1		
NPM	5.4	6.6	6.4	6.9		
RoE	22.9	25.7	22.0	21.8		
RoCE	23.2	25.8	24.5	27.9		
Per share data (Rs)						
O/s shares	35.5	35.5	35.5	35.5		
EPS	28.5	41.6	44.6	53.9		
FDEPS	28.5	41.6	44.6	53.9		
CEPS	41.3	54.9	58.3	68.3		
BV	124.6	162.2	202.8	247.3		
DPS	6.0	6.0	7.0	8.0		
Valuation ratios (x)						
PE	44.2	30.3	28.3	23.4		
P/BV	10.1	7.8	6.2	5.1		
EV/EBITDA	20.7	17.6	16.5	13.3		
EV/Sales	2.4	2.0	1.8	1.6		
Other key ratios						
D/E (x)	0.9	0.7	0.5	0.3		

Source: Company, Kotak Securities - Private Client Research



#### **RATING SCALE**

# **Definitions of ratings**

BUY - We expect the stock to deliver more than 15% returns over the next 12 months

ADD — We expect the stock to deliver 5% - 15% returns over the next 12 months

**REDUCE** – We expect the stock to deliver -5% - +5% returns over the next 12 months

SELL – We expect the stock to deliver < -5% returns over the next 12 months

NR – Not Rated. Kotak Securities is not assigning any rating or price target to the stock.

The report has been prepared for information purposes only.

**SUBSCRIBE** – We advise investor to subscribe to the IPO.

RS - Rating Suspended. Kotak Securities has suspended the investment rating and price target

for this stock, either because there is not a sufficient fundamental basis for determining, or there are legal, regulatory or policy constraints around publishing, an investment rating or target. The previous investment rating and price target, if any, are no longer in effect for this

stock and should not be relied upon.

NA - Not Available or Not Applicable. The information is not available for display or is not

applicable

NM – Not Meaningful. The information is not meaningful and is therefore excluded.

NOTE – Our target prices are with a 12-month perspective. Returns stated in the rating scale are our

internal benchmark.

# **FUNDAMENTAL RESEARCH TEAM**

Rusmik Oza

Head of Research rusmik.oza@kotak.com +91 22 6218 6441

Sanjeev Zarbade

Cap. Goods & Cons. Durables sanjeev.zarbade@kotak.com +91 22 6218 6424

Sumit Pokharna

Oil and Gas, Information Tech sumit.pokharna@kotak.com +91 22 6218 6438 **Arun Agarwal** 

Auto & Auto Ancillary arun.agarwal@kotak.com +91 22 6218 6443

Jatin Damania

Metals & Mining, Midcap jatin.damania@kotak.com +91 22 6218 6440

Pankaj Kumar

Midcap pankajr.kumar@kotak.com +91 22 6218 6434 **Amit Agarwal** 

Transportation, Paints, FMCG agarwal.amit@kotak.com +91 22 6218 6439

Deval Shah

Research Associate deval.shah@kotak.com +91 22 6218 6425

Krishna Nain

M&A, Corporate actions krishna.nain@kotak.com +91 22 6218 7907 K. Kathirvelu

Support Executive k.kathirvelu@kotak.com +91 22 6218 6427

#### **TECHNICAL RESEARCH TEAM**

Shrikant Chouhan

shrikant.chouhan@kotak.com +91 22 6218 5408 Amol Athawale

amol.athawale@kotak.com +91 20 6620 3350 Faisal Shaikh, FRM, CFTe

Research Associate faisalf.shaikh@kotak.com +91 22 62185499 Siddhesh Jain

Research Associate siddhesh.jain@kotak.com +91 22 62185498

# **DERIVATIVES RESEARCH TEAM**

Sahaj Agrawal

sahaj.agrawal@kotak.com +91 79 6607 2231 Malay Gandhi

malay.gandhi@kotak.com +91 22 6218 6420 Prashanth Lalu

prashanth.lalu@kotak.com +91 22 6218 5497 Prasenjit Biswas, CMT, CFTe prasenjit.biswas@kotak.com

+91 33 6625 9810



#### Disclosure/Disclaimer

Kotak Securities Limited established in 1994, is a subsidiary of Kotak Mahindra Bank Limited. Kotak Securities is one of India's largest brokerage and distribution

Kotak Securities Limited is a corporate trading and clearing member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), Metropolitan Stock Exchange of India Limited (MSE), National Commodity and Derivatives Exchange (NCDEX) and Multi Commodity Exchange (MCX). Our businesses include stock broking, services rendered in connection with distribution of primary market issues and financial products like mutual funds and fixed deposits, depository services and Portfolio Management.

Kotak Securities Limited is also a depository participant with National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL). Kotak Securities Limited is also registered with Insurance Regulatory and Development Authority as Corporate Agent for Kotak Mahindra Old Mutual Life Insurance Limited and is also a Mutual Fund Advisor registered with Association of Mutual Funds in India (AMFI). We are registered as a Research Analyst under SEBI (Research Analyst) Regulations, 2014.

We hereby declare that our activities were neither suspended nor we have defaulted with any stock exchange authority with whom we are registered in last five years. However SEBI, Exchanges and Depositories have conducted the routine inspection and based on their observations have issued advise/warning/deficiency letters/ or levied minor penalty on KSL for certain operational deviations. We have not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has our certificate of registration been cancelled by SEBI at any point of time.

We offer our research services to clients as well as our prospects

This document is not for public distribution and has been furnished to you solely for your information and must not be reproduced or redistributed to any other person. Persons into whose possession this document may come are required to observe these restrictions.

This material is for the personal information of the authorized recipient, and we are not soliciting any action based upon it. This report is not to be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It is for the general information of clients of Kotak Securities Ltd. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients.

We have reviewed the report, and in so far as it includes current or historical information, it is believed to be reliable though its accuracy or completeness cannot be guaranteed. Neither Kotak Securities Limited, nor any person connected with it, accepts any liability arising from the use of this document. The recipients of this material should rely on their own investigations and take their own professional advice. Price and value of the investments referred to in this material may go up or down. Past performance is not a guide for future performance. Certain transactions -including those involving futures, options and other derivatives as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. Reports based on technical analysis centers on studying charts of a stock's price movement and trading volume, as opposed to focusing on a company's fundamentals and as such, may not match with a report on a company's fundamentals.

Opinions expressed are our current opinions as of the date appearing on this material only. While we endeavor to update on a reasonable basis the information discussed in this material, there may be regulatory, compliance or other reasons that prevent us from doing so. Prospective investors and others are cautioned that any forward-looking statements are not predictions and may be subject to change without notice. Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

Kotak Securities Limited has two independent equity research groups: Institutional Equities and Private Client Group. This report has been prepared by the Private Client Group.

We and our affiliates/associates, officers, directors, and employees, Research Analyst(including relatives) worldwide may: (a) from time to time, have long or short positions in, and buy or sell the securities thereof, of company (ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company/company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) or have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of Research Report or at the time of public appearance. Kotak Securities Limited (KSL) may have proprietary long/short position in the above mentioned scrip(s) and therefore may be considered as interested. The views provided herein are general in nature and does not consider risk appetite or investment objective of particular investor; readers are requested to take independent professional advice before investing. This should not be construed as invitation or solicitation to do business with KSL. Kotak Securities Limited is also a Portfolio Manager. Portfolio Management Team (PMS) takes its investment decisions independent of the PCG research and accordingly PMS may have positions contrary to the PCG research recommendation. Kotak Securities Limited does not provide any promise or assurance of favourable view for a particular industry or sector or business group in any manner. The investor is requested to take into consideration all the risk factors including their financial condition, suitability to risk return profile and take professional advice before investing.

The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

No part of this material may be duplicated in any form and/or redistributed without Kotak Securities' prior written consent.

Details of Associates are available on www.kotak.com

- 1. "Note that the research analysts contributing to the research report may not be registered/qualified as research analysts with FINRA; and
- 2. Such research analysts may not be associated persons of Kotak Mahindra Inc and therefore, may not be subject to NASD Rule 2711 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account

Any U.S. recipients of the research who wish to effect transactions in any security covered by the report should do so with or through Kotak Mahindra Inc. (Member FINRA/SIPC) and (ii) any transactions in the securities covered by the research by U.S. recipients must be effected only through Kotak Mahindra Inc. (Member FINRA/SIPC) at 369 Lexington Avenue 28th Floor NY NY 10017 USA (Tel:+1 212-600-8850).

Kotak Securities Limited and its non US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non US issuers, prior to or immediately following its publication. This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. This research report and its respective contents do not constitute an offer or invitation to purchase or subscribe for any securities or solicitation of any investments or investment services. Accordingly, any brokerage and investment services including the products and services described are not available to or intended for Canadian persons or US persons."

Research Analyst has served as an officer, director or employee of subject company(ies): No

We or our associates may have received compensation from the subject company(ies) in the past 12 months.

We or our associates have managed or co-managed public offering of securities for the subject company(ies) in the past 12 months: No

We or our associates may have received compensation for investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months. We or our associates may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months. We or our associates may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report. Our associates may have financial interest in the subject company(ies).

Research Analyst or his/her relative's financial interest in the subject company(ies): No

Kotak Securities Limited has financial interest in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No

Nature of financial interest is holding of equity shares or derivatives of the subject company.

Our associates may have actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.

Research Analyst or his/her relatives has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No.

Kotak Securities Limited has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No



By referring to any particular sector, Kotak Securities Limited does not provide any promise or assurance of favourable view for a particular industry or sector or business group in any manner. The investor is requested to take into consideration all the risk factors including their financial condition, suitability to risk return profile and take professional advice before investing. Such representations are not indicative of future results.

Subject company(ies) may have been client during twelve months preceding the date of distribution of the research report.

"A graph of daily closing prices of securities is available at <a href="https://www.nseindia.com/ChartApp/install/charts/mainpage.jsp">https://www.nseindia.com/ChartApp/install/charts/mainpage.jsp</a> and <a href="https://economictimes.indiatimes.com/markets/stocks/stock-quotes.">https://economictimes.indiatimes.com/markets/stocks/stock-quotes.</a> (Choose a company from the list on the browser and select the "three years" icon in the price chart)."

Kotak Securities Limited. Registered Office: 27 BKC, C 27, G Block, Bandra Kurla Complex, Bandra (E), Mumbai 400051. CIN: U99999MH1994PLC134051, Telephone No.: +22 43360000, Fax No.: +22 67132430. Website: www.kotak.com/www.kotaksecurities.com. Correspondence Address: Infinity IT Park, Bldg. No 21, Opp. Film City Road, A K Vaidya Marg, Malad (East), Mumbai 400097. Telephone No: 42856825. SEBI Registration No: INZ000200137 (Member ID: NSE-08081; BSE-673; MSE-1024; MCX-56285; NCDEX-1262), AMFI ARN 0164, PMS INP000000258 and Research Analyst INH000000586. NSDL/CDSL: IN-DP-NSDL-23-97. Our research should not be considered as an advertisement or advice, professional or otherwise. The investor is requested to take into consideration all the risk factors including their financial condition, suitability to risk return profile and the like and take professional advice before investing. Investments in securities market are subject to market risks, read all the related documents carefully before investing. Derivatives are a sophisticated investment device. The investor is requested to take into consideration all the risk factors before actually trading in derivative contracts. Compliance Officer Details: Mr. Manoj Agarwal. Call: 022 - 4285 8484, or Email: ks.compliance@kotak.com.

In case you require any clarification or have any concern, kindly write to us at below email ids:

- Level 1: For Trading related queries, contact our customer service at 'service.securities@kotak.com' and for demat account related queries contact us at ks.demat@kotak.com or call us on: Toll free numbers 18002099191 / 1860 266 9191
- Level 2: If you do not receive a satisfactory response at Level 1 within 3 working days, you may write to us at ks.escalation@kotak.com or call us on 022-42858445 and if you feel you are still unheard, write to our customer service HOD at ks.servicehead@kotak.com or call us on 022-42858208.
- Level 3: If you still have not received a satisfactory response at Level 2 within 3 working days, you may contact our Compliance Officer (Mr. Manoj Agarwal) at ks.compliance@kotak.com or call on 91- (022) 4285 8484.
- Level 4: If you have not received a satisfactory response at Level 3 within 7 working days, you may also approach CEO (Mr. Kamlesh Rao) at ceo.ks@kotak.com or call on 91- (022) 4285 8301.